吸入沙美特罗/氟替卡松或福莫特罗/布地奈德对支气管哮喘慢性持续期的疗效评价

目的 观察吸入沙美特罗/氟替卡松和福莫特罗/布地奈德对支气管哮喘慢性持续期的疗效.方法 将120例中度支气管哮喘慢性持续期的患者随机分为两组,一组吸入沙美特罗/氟替卡松(50/250),250 μg/次,2次/d,另一组吸入福莫特罗/布地奈德,(4.5/160),160 μg/次,2次/d.评价3个月、6个月内的急性发作次数、夜间发作次数、使用短效β2受体激动剂的次数和哮喘控制调查表评分.结果 治疗3月的沙美特罗组急性发作次数、使用短效β2受体激动剂的次数和哮喘控制调查表评分多于布地奈德组,夜间发作次数少于布地奈德组,但差异没有统计学意义;治疗6月时沙美特罗组急性发作次数、夜间发作次数、使用短效β2受体激动剂的次数和哮喘控制调查表评分均少于布地奈德组,但差异仍没有统计学意义.结论 中度支气管哮喘慢性持续期的患者吸入沙美特罗/氟替卡松或福莫特罗/布地奈德干粉剂均能取得同样的哮喘控制.

Assessment of efficacy for asthma in chronic persistent period by inhaled Salmeterol/Fluticasone or Budesonide/Formoterol

Objective To observe the effect on asthma in moderate chronic persistent period by inhaled Salmeterol/Fluticasone(SFC) or Budesonide/Formoterol(BDF).Methods 120 moderate asthma in chronic persistent period were divided into two groups,one group was inhaled SFC(50/250),250 μg/time,2 times/day;and the other was inhaled BDF(160/4.5),160 μg/time,2 times/day.Times of the asthma acute episode,time of episode at night,using times of short-acting β2-receptor agonist and Asthma Control Questionaire marks(ACQM) were assessed in 3 months and 6 months.Results Compared with BDF group,times of episode at night was less,but the acute episode times,using times of short-acting β2-receptor agonist and ACQM was more in SFC group in 3 months,and the diffirences between the two groups were no statistical signiffecance;after 6 months in SFC group,imes of episode at night,the acute episode times,using times of short-acting β2-receptor agonist and ACQM were less than those in BDF,the diffirences were still no statistical signiffecance.Conclusions Asthma in moderate chronic persistent period treated by inhalaion SFC or BDF could attained the same equal asthma control.